• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ulcerative Colitis - Pipeline Review, Q1 2011 - Product Image

Ulcerative Colitis - Pipeline Review, Q1 2011

  • Published: February 2011
  • 86 pages
  • Global Markets Direct

Ulcerative Colitis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Ulcerative Colitis - Pipeline Review, Q1 2011', provides an overview of the Ulcerative Colitis therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. 'Ulcerative Colitis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ulcerative Colitis.
- A review of the Ulcerative Colitis products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ulcerative Colitis Overview
Therapeutics Development
An Overview of Pipeline Products for Ulcerative Colitis
Ulcerative Colitis Therapeutics under Development by Companies
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Ulcerative Colitis Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Biogen Idec Inc.
Athersys, Inc.
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Mochida Pharmaceutical Co., Ltd.
Sylentis
Histogen, Inc.
Novartis AG
Astellas Pharma Inc.
Elan Corporation, plc
Pfizer Inc.
Warner Chilcott Limited
Zeria Pharmaceutical Co Ltd
Genmab A/S
Bayer AG
4SC AG
Alizyme plc
Hollis-Eden Pharmaceuticals, Inc.
Karo Bio
Callisto Pharmaceuticals, Inc.
Ore Pharmaceuticals Inc
Cosmo Pharmaceuticals S.p.A
Cerimon Pharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc.
Pluristem Therapeutics Inc.
LTT Bio-Pharma Co., Ltd.
InDex Pharmaceuticals AB
ActogeniX NV
Am-Pharma B.V.
7TM Pharma A/S
Grupo Uriach
PLx Pharma Inc.
AmKor Pharma, Inc.
Txcell SA
Atlantic Pharmaceuticals, Inc.
S.L.A. Pharma AG
TikoMed AB
Dr. Falk Pharma GmbH
Ferring Pharmaceuticals, Inc.
Kemin Industries, Inc.
Altheus Therapeutics, Inc.
LIPID THERAPEUTICS GmbH
Immune Technologies and Medicine
Sigmoid Pharma.
Universities/Institutes Involved in Ulcerative Colitis Therapeutics Development
Ulcerative Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Asacol 400 mg Delayed-Release Tablets - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide MMX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COLAL-PRED - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMPL-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPC-6535 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Orencia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentasa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simponi - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vedolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Z-206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
5-ASA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-ASA + Tacrolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Ulcerative Colitis - Featured News
1. Nov 08, 2010: Santarus Announces Positive Phase III Clinical Trial Results Of Budesonide MMX In Ulcerative Colitis Patients
2. Nov 08, 2010: Santarus Announces Positive Phase III Clinical Trial Results Of Budesonide MMX In Ulcerative Colitis Patients
3. Nov 08, 2010: Athersys Announces FDA Authorization Of Phase II Clinical Trial For Inflammatory Bowel Disease With Pfizer Regenerative Medicine
4. Nov 04, 2010: 4SC's Vidofludimus Phase IIa Study In IBD Meets Primary Endpoint
5. Sep 30, 2010: Cosmo And Santarus Announce Positive Results In US Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis
6. Sep 29, 2010: Santarus And Cosmo Announce Positive Results From US Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis
7. Jul 08, 2010: Lialda Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
8. Jun 10, 2010: PurGenesis Initiates Phase IIa Trial Of PUR0110 For Treatment Of Mild-to-Moderate Distal Ulcerative Colitis
9. May 28, 2010: Shire Receives LIALDA Paragraph IV Notice Letter from Zydus Pharmaceuticals
10. May 06, 2010: PurGenesis Announces Positive Results From Phase I Clinical Trial of PUR0110 for Ulcerative colitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Ulcerative Colitis, 2011
Products under Development for Ulcerative Colitis – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Johnson & Johnson, 2011
F. Hoffmann-La Roche Ltd., 2011
Abbott Laboratories, 2011
Biogen Idec Inc., 2011
Athersys, Inc., 2011
GlaxoSmithKline plc, 2011
Takeda Pharmaceutical Company Limited, 2011
Mochida Pharmaceutical Co., Ltd., 2011
Sylentis, 2011
Histogen, Inc., 2011
Novartis AG, 2011
Astellas Pharma Inc., 2011
Elan Corporation, plc, 2011
Pfizer Inc., 2011
Warner Chilcott Limited, 2011
Zeria Pharmaceutical Co Ltd, 2011
Genmab A/S, 2011
Bayer AG, 2011
4SC AG, 2011
Alizyme plc, 2011
Hollis-Eden Pharmaceuticals, Inc., 2011
Karo Bio, 2011
Callisto Pharmaceuticals, Inc., 2011
Ore Pharmaceuticals Inc, 2011
Cosmo Pharmaceuticals S.p.A, 2011
Cerimon Pharmaceuticals, Inc., 2011
RegeneRx Biopharmaceuticals, Inc., 2011
Pluristem Therapeutics Inc., 2011
LTT Bio-Pharma Co., Ltd., 2011
InDex Pharmaceuticals AB, 2011
ActogeniX NV, 2011
Am-Pharma B.V., 2011
7TM Pharma A/S, 2011
Grupo Uriach, 2011
PLx Pharma Inc., 2011
AmKor Pharma, Inc., 2011
Txcell SA, 2011
Atlantic Pharmaceuticals, Inc., 2011
S.L.A. Pharma AG, 2011
TikoMed AB, 2011
Dr. Falk Pharma GmbH, 2011
Ferring Pharmaceuticals, Inc., 2011
Kemin Industries, Inc., 2011
Altheus Therapeutics, Inc., 2011
LIPID THERAPEUTICS GmbH, 2011
Immune Technologies and Medicine, 2011
Sigmoid Pharma., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Ulcerative Colitis, 2011
Products under Development for Ulcerative Colitis – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos